Fungal infections, mainly caused by Aspergillus species 1 as well as severe GVHD are the most serious long-term complications after allo-SCT. They frequently occur simultaneously due to the profound immunodeficiency in GVHD or to pulmonary involvement such as in patients suffering from bronchiolitis obliterans (BO), a severe manifestation of chronic pulmonary GVHD. Therefore, new treatment approaches involving immunomodulation are urgently needed.
Here, we report efficacy and tolerability of a supportive treatment option with IFN-g in patients with relapsing infections after allo-SCT and discuss a potential beneficial effect in concomitant BO.
In a pilot series, five patients (two females/three males), after allo-SCT, suffering from recurrent infections of the lung without (n ¼ 2) or with (n ¼ 3) BO and resistant to at least two antimycotic or antibiotic drugs received a total of seven courses of s.c. injections of IFN-g three times a week (50 or 100 mg/day) for an average of 166 days (21-363 days), whereas antiinfectious treatment remained unchanged. Indications were treatment-resistant invasive aspergillosis (two patients with pulmonary, one sinusoidal and one of them with concomitant BO), atypical mycobacterial infection (one patient with BO) and therapy-resistant and ventilator-dependent BO with bacterial superinfection (one additional patient). Treatment was started between 21 and 2056 days after allo-SCT. Concomitant chronic GVHD was present in three of five patients; four of five patients were on immunosuppression with prednisolone alone or different combinations of everolimus, tacrolimus, MMF or CYA with or without prednisolone ( Table 1) .
Diagnosis and monitoring of infections and pulmonary GVHD was performed radiologically with computed tomography (CT) scans, determination of Aspergillus Ag in the serum, pulmonary function tests (PFT) and blood gas analyses in case of ventilation. All cases of invasive aspergillosis fulfilled criteria of probable invasive aspergillosis according to the EORTC/MSG criteria. 2 Infectious manifestations improved clinically and radiologically in all patients during IFN-g treatment. On detail, the patient with atypical pulmonary mycobacteriosis showed a significant clinical stabilization of pulmonary symptoms and a cure of caverns in CT, allowing the termination of tuberculostatic therapy. Relapsing fungal pansinusitis with typical mycotic lesions in CT scan vanished. Four treatment courses were given to two patients with relapsing invasive pulmonary aspergillosis indicated by typical radiological lesions and elevated Aspergillus Ag. In all treatment courses, CT scans showed resolution of aspergillosis signs after treatment and Aspergillus Ag decreased from 6.0 to normal value (0.3).
Bronchiolitis obliterans was diagnosed by typical lesions in CT scan and moderately-to-severely impaired PFT in three patients. CT from one patient with BO proven by PFT ( Figure 1 ) revealed concomitant lesions from BO and organizing pneumonia. During IFN-g treatment, CT signs of BO and organizing pneumonia improved in two patients and were stable in the third patient. Clinically obstructive symptoms such as dyspnea or cough improved in all three patients and one patient, who initially needed oxygen, became oxygen independent, although obstruction did not objectively change in PFT. One patient who had to be ventilated because of superinfection of severe BO and who was refractory to antibacterial and antifungal treatment was able to be weaned, with improvement of hypercapnia in blood gas analyses from 4100 mm Hg on ventilation to 55 mm Hg with 2 L of oxygen per min without initiation of additional treatment after start of IFN-g treatment.
With regard to side effects, IFN-g was well tolerated at full dose in three out of five treated patients. In one patient, a dose reduction had to be made because of fever, chills and fatigue and in another patient, the treatment was switched from s.c. to inhalative application because of increasing liver enzymes. There were no negative effects on symptoms of GVHD in all patients. Beside moderate anemia in one patient, there were no significant hematological side effects.
Our results suggest that IFN-g can be safely administered as a supplementary therapy to treat fungal infections resistant to antimycotic treatment after allo-SCT. This is in line with two recent reports on successful use of IFN-g as an additive treatment in hematological and SCT patients with fungal infections resistant to conventional antimycotic treatment. 3, 4 As IFN-g is thought to be a typical Th1 cytokine, deterioration of GVHD was a theoretical concern. However, current data suggest IFN-g to be a major immunoregulatory cytokine, potentially dampening inflammation and GVHD. 5 Besides its limiting effect on T-cell expansion and on the induction of regulatory T and NK-cell populations, another possible immunosuppressive pathway could involve the induction of the enzyme indoleamine 2,3-dioxygenase (IDO). IDO is an intracellular enzyme that catalyzes the essential amino acid tryptophan to kynurenines. The enzyme is induced by inflammatory cytokines such as IFN-g and shows immunosuppressive function in mouse models. 6 In line with this, several reports indicate more severe overall 7, 8 or at least pulmonary GVHD 9 in mice receiving T cells from IFN-g knockout donors. In addition, modulation and improvement of epithelial defence might be a further mechanism of protection. We showed a correlation between occurrence of BO with loss of function mutations of the NOD2/CARD15 gene, an important pattern recognition receptor for bacterial ligands. 10 As IFN-g induces epithelial NOD2/CARD15 expression and NOD2/CARD15 is the most important regulator of epithelial production of the antimicrobial defensin peptides, IFN-g might directly contribute to improved epithelial defence. In conclusion, our results show that IFN-g can be an important supportive treatment option in invasive aspergillosis after allo-SCT. In addition, we suggest a positive immunomodulating effect of IFN-g through increasing local defensin production or induction of IDO in chronic pulmonary GVHD. Defined clinical trials as well as further functional studies with larger numbers of patients are needed to evaluate the efficacy and mechanism of IFN-g function. Owing to limited treatment options and the impaired prognosis of chronic pulmonary GVHD after allo-SCT, an immunomodulating therapy with IFN-g may present a novel and important treatment option.
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